1. Compared to alisertib alone, adding alisertib to fulvestrant did not increase objective tumour response rates to treatment nor progression-free survival. ...
Click to read this study in The Lancet Oncology.
1. Median progression free survival was longer in the fulvestrant and palbociclib group compared to the aromatase inhibitor plus palbociclib ...
Click to read this study in The Lancet Oncology.
Click to read this study in The Lancet Oncology.
Click to read this study in Lancet Oncology.
Click here to read this study in JAMA Oncology.
1. Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer patients who have a mutated ...
1. A randomized control trial of patients with hormone receptor-positive metastatic breast cancer compared survival outcomes between patients who received ...
1. A randomized control trial of patients with hormone receptor-positive metastatic breast cancer compared survival outcomes between patients who received ...
